US shoulders disproportionate cost of new medications, report finds

The report from the Office of Health Policy highlights that Americans bear an overwhelming financial burden when it comes to new medications, accounting for almost 80% of the revenue generated by innovative drugs. This raises significant concerns about the economic fairness and sustainability of the pharmaceutical pricing system. As the US continues to invest heavily in drug development, understanding the implications for healthcare costs and access to life-saving treatments becomes crucial for policymakers and healthcare stakeholders.